At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 93 enrolled
Drug / intervention
Azacitidinedrug
Likely dose
Azacitidine 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)
In Brief
A Phase 2 clinical trial evaluating Azacitidine for Acute Myelocytic Leukemia and Myelodysplastic Syndrome. Completed, enrolled 93 participants across 11 sites.
Detailed Summary
Assessment of efficacy of azacitidine to prevent a relapse
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
First PostedOct 2011
Primary CompletionAug 2018
Study CompletionFeb 2021
TodayJul 2026
First PostedOct 31, 2011
Enrollment StartSep 1, 2011
Primary CompletionAug 1, 2018
Study CompletionFeb 1, 2021
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 14.7 years ago
Interventions
Azacitidinedrug
Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles